Table 1:
Overall characteristics of the study population
| Characteristics | |
|---|---|
| Patient characteristics | |
| Age (mean) (range) | 64.6 ± 12.6 (29–86) |
| Male sex (No./No.) (%) | 69/95 (72.6%) |
| Left-hemisphere stroke (No./No.) (%) | 56/95 (58.9%) |
| Baseline NIHSS (mean) (range) | 16.8 ± 5.5; 2–32 |
| Baseline ASPECTS (median) (range) | 8; 2–10 |
| Tobacco (No./No.) (%) | 35/95 (36.8%) |
| Diabetes mellitus (No./No.) (%) | 7/95 (7.4%) |
| Dyslipidemia (No./No.) (%) | 16/95 (16.8%) |
| Atrial fibrillation at admission (No./No.) (%) | 10/95 (10.5%) |
| Prestroke antiplatelet therapy (No./No.) (%) | 21/95 (22.1%) |
| Procedural and postprocedural characteristics | |
| Onset-to-groin time (mean) (range) | 284.5 ± 156.4; 70–980 min |
| Onset-to-recanalization (mean) (range) | 376.7 ± 168.3; 110–1075 min |
| Procedural time (mean) (range) | 90.6 ± 58.2; 9–315 min |
| No. of MT attempts (mean) (range) | 2.57 ± 1.7; 1–10 |
| Successful recanalization mTICI ≥2b (No./No.) (%) | 58/95 (61.1%) |
| Intravenous thrombolysis (No./No.) (%) | 45/95 (47.4%) |
| Single-layer carotid stent (No./No.) (%) | 87/95 (91.6%) |
| Dual-layer carotid stent (No./No.) (%) | 8/95 (8.4%) |
| Intraprocedural heparin (No./No.) (%) | 40/95 (42.1%) |
| Intraprocedural single-antiplatelet therapy (No./No.) (%) | 46/79 (58.2%) |
| Intraprocedural dual-antiplatelet therapy (No./No.) (%) | 10/43 (23.3%) |
| Postprocedural single-antiplatelet therapy (No./No.) (%) | 25/54 (46.3%) |
| Postprocedural dual-antiplatelet therapy (No./No.) (%) | 30/60 (50%) |
| Symptomatic ICH | 26/94 (27.7%) |
Note:—mTICI indicates modified TICI.